Calendario›REGN›Olatorepatide

Olatorepatide

Efficacy and Safety of Olatorepatide Versus Placebo in Adults With Moderate to Severe Hidradenitis Suppurativa Living With Overweight or Obesity

Ensayo de REGENERON PHARMACEUTICALS, INC. en Hidradenitis supurativa.

Más ensayos de: Hidradenitis supurativa.

Fase

Fase 2

Estado

Aún sin reclutar

Participantes

300

previstos

Fin del objetivo primario

nov 2028

estimado por el promotor

Qué significa cada fase y cada estado.

Estudio de intervención, aleatorizado, cuádruple ciego. Comenzó en oct 2026.

Qué mide

Percent change in total Abscess and inflammatory Nodule (AN) count (From baseline to week 52) (del registro, en inglés)

Cómo lo describe el promotor

En el documentoEn inglés, del registroThis study will test an experimental Regeneron drug called olatorepatide ("study drug") to see if it can help treat Hidradenitis Suppurativa (HS). In this study, olatorepatide is being tested in people with HS and living with overweight or obesity to see if it helps improve their HS symptoms and quality of life and helps support weight loss. The study is looking at: * What side effects olatorepatide might cause * How well olatorepatide works * How much olatorepatide is in the blood at different times * If the body makes antibodies to olatorepatide, which may cause olatorepatide to not work as well

Más ensayos de REGN

Todos los de REGN, en su ficha.

Ficha completa en ClinicalTrials.gov (NCT07830329), actualizada en sep 2026.